Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

Interest Coverage No Debt
MGNX's Interest Coverage is ranked higher than
66% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MGNX' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: No Debt
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MGNX's 10-Y Financials

Financials (Next Earnings Date: 2017-02-28)

Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MGNX Guru Trades in Q1 2016

Steven Cohen 2,330,200 sh (+10.34%)
Ronald Muhlenkamp 67,245 sh (+1.26%)
John Griffin 1,360,000 sh (+0.74%)
George Soros 19,488 sh (unchged)
Julian Robertson 575,129 sh (unchged)
First Eagle Investment 285,800 sh (-1.45%)
Jim Simons 20,723 sh (-77.64%)
» More
Q2 2016

MGNX Guru Trades in Q2 2016

Paul Tudor Jones 12,858 sh (New)
Steven Cohen 2,554,900 sh (+9.64%)
John Griffin 1,360,000 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
First Eagle Investment 221,800 sh (-22.39%)
Julian Robertson 313,140 sh (-45.55%)
Ronald Muhlenkamp 15,835 sh (-76.45%)
» More
Q3 2016

MGNX Guru Trades in Q3 2016

Paul Tudor Jones 15,542 sh (+20.87%)
First Eagle Investment 221,800 sh (unchged)
John Griffin 1,360,000 sh (unchged)
Julian Robertson 266,067 sh (-15.03%)
Ronald Muhlenkamp 12,162 sh (-23.20%)
Steven Cohen 1,813,300 sh (-29.03%)
» More
Q4 2016

MGNX Guru Trades in Q4 2016

Ronald Muhlenkamp 12,803 sh (+5.27%)
John Griffin 1,360,000 sh (unchged)
Paul Tudor Jones 14,959 sh (-3.75%)
Julian Robertson 239,667 sh (-9.92%)
First Eagle Investment 175,000 sh (-21.10%)
Steven Cohen 1,213,117 sh (-33.10%)
» More
» Details

Insider Trades

Latest Guru Trades with MGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Traded in other countries:M55.Germany,
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

Macrogenics Inc was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company, engaged in discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The Company currently has a manufacturing facility located in Rockville, Maryland. The Company has three versatile, proprietary technology platforms consisting of: its Dual Affinity Re-Targeting ("DART") platform, which enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, and also includes the ability to recruit any T cell in a patient's body to destroy targeted cancer cells; its Fc Optimization platform, which enhances the body's immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular cytotoxicity ("ADCC") in which antibodies and immune cells cooperate to destroy targets such as tumor cells; and its Cancer Stem-like Cell ("CSLC") platform, which provides a discovery tool to identify cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them. It currently has two oncology product candidates in clinical development. The product candidates are subject to regulation in the United States by the Food and Drug Administration as biological products.



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $94.95
EPS (TTM) $ -1.63
Short Percentage of Float9.52%
52-Week Range $14.85 - 33.30
Shares Outstanding (Mil)34.84

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 98 44 52 105
EPS ($) -1.48 -3.32 -3.32 -2.60
EPS without NRI ($) -1.48 -3.32 -3.32 -2.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
Dividends per Share ($)
» More Articles for MGNX


Articles On GuruFocus.com
Julian Robertson Sells Delta Air Lines, Alphabet Dec 07 2016 
Ronald Muhlenkamp Sells Allegiant, Microsoft, Apple Aug 15 2016 
Weekly 3-Year Low Highlights: KN, MGNX, MIXT, EDMC May 27 2014 

More From Other Websites
MacroGenics Announces Date of Fourth Quarter and Full Year 2016 Financial Results Conference Call Feb 16 2017
MacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference Feb 09 2017
3 Greater Washington biotech execs sign industry letter opposing the Trump travel ban Feb 08 2017
MACROGENICS INC Files SEC form 8-K, Financial Statements and Exhibits Jan 26 2017
MacroGenics Announces Appointments to Board of Directors Jan 25 2017
D.C.-area biotech stocks fall on Trump's tough talk on industry Jan 11 2017
5 Stocks Setting Up for Big Breakouts Jan 06 2017
MacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA Jan 05 2017
MacroGenics’ MGD006 Granted Orphan Drug Status for AML by FDA Jan 05 2017
MacroGenics to Present at the 35th Annual J.P. Morgan Healthcare Conference Jan 05 2017
Coverage initiated on MacroGenics by SunTrust Dec 20 2016
MACROGENICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 13 2016
MacroGenics Highlights Progress at 2016 R&D Day Dec 13 2016
MacroGenics Licenses Synthon’s Technology to Develop an Anti-B7-H3 ADC Dec 12 2016
Do Hedge Funds Love MacroGenics Inc (MGNX)? Dec 09 2016
MacroGenics to Host 2016 R&D Day Dec 08 2016
MacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : December 7, 2016 Dec 07 2016
MacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : December 6,... Dec 06 2016
MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : November 22,... Nov 22 2016
MACROGENICS INC Financials Nov 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)